logo-loader

PharmaDrug forms clinical research collaboration with Johns Hopkins University

Published: 12:23 25 Aug 2021 EDT

PharmaDrug Inc CEO Daniel Cohen tells Proactive the group has formed a clinical trial agreement with the Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed, potently active comparator molecule.

Cohen says the Toronto-based company's clinical research collaboration builds upon its existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body.

It has an exclusive option to obtain a commercialization license to all rights, title, and interest that JHU may have or obtain in any invention that results from the clinical study.

Pharmadrug CEO says completion of cGMP substance manufacturing advances its...

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen joined Proactive's Stephen Gunnion with the news that the company has completed cGMP (good manufacturing practices) production of a multi-kilogram batch of cepharanthine-2HCl, a key ingredient in PD-001, the oral version of...

on 10/04/2022